Biogen stops testing Tysabri to treat stroke after study fails

(Reuters) – Biogen Inc will stop testing established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study, the U.S. drugmaker said on Wednesday.

Source: Reuters Medical News